Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers

scientific article published on 20 January 2020

Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41598-020-57534-5
P932PMC publication ID6971072
P698PubMed publication ID31959902

P50authorThai Huu HoQ57130809
James J HsiehQ88029561
Morgan RouprêtQ88883209
P2093author name stringSatish K Tickoo
Jean-Philippe Spano
Hui Yao
David Khayat
Xiaoping Su
Paul Russo
Ying-Bei Chen
Yiyu Dong
Eva Compérat
Jose A Karam
Nizar M Tannir
Roger Mouawad
Ronan Flippot
Gabriel G Malouf
Kyle A Blum
Roy Mano
Abraham A Hakimi
Renzo G Dinatale
P2860cites workComprehensive molecular characterization of clear cell renal cell carcinomaQ27852374
Integrated molecular analysis of clear-cell renal cell carcinomaQ27852382
A method and server for predicting damaging missense mutationsQ27860835
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics dataQ28266682
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortalQ28288215
TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomasQ33688439
KRAS and YAP1 converge to regulate EMT and tumor survivalQ33946244
Structure and function of SWI/SNF chromatin remodeling complexes and mechanistic implications for transcriptionQ34074890
Signaling pathways in renal cell carcinomaQ34978827
Predicting the functional impact of protein mutations: application to cancer genomicsQ35224321
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular OncologyQ35584856
The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domainQ36236290
SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repairQ36320349
Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinomaQ36365688
Chromatin remodeling in cancer: a gateway to regulate gene transcriptionQ36511855
Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinomaQ36646352
Twist-mediated Epithelial-mesenchymal Transition Promotes Breast Tumor Cell Invasion via Inhibition of Hippo PathwayQ36814799
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.Q37330688
The Hippo pathway and human cancer.Q38087215
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parametersQ38136413
Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile and transcriptional landscapeQ38678106
mTOR Signaling in Growth, Metabolism, and Disease.Q38747508
YAP modulates TGF-β1-induced simultaneous apoptosis and EMT through upregulation of the EGF receptorQ38829202
Hippo signaling in the kidney: the good and the bad.Q38838116
The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer.Q38907037
A conditional mouse model for malignant mesotheliomaQ40004544
Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancersQ41871593
Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinibQ44269222
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapyQ46209280
Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.Q47631332
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.Q47916891
NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell CarcinomasQ48015099
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.Q52321029
Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.Q52642770
Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers.Q52726723
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in CancerQ58093858
Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy SamplesQ88627382
P433issue1
P921main subjectrenal cell carcinomaQ1164529
P304page(s)701
P577publication date2020-01-20
P1433published inScientific ReportsQ2261792
P1476titleMolecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers
P478volume10

Reverse relations

cites work (P2860)
Q90690759Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC): A Distinctive Neoplasm Associated With Somatic NF2 Mutations
Q100533974Sarcomatoid renal cell carcinoma: biology, natural history and management
Q97523716The Effect of Chinese Traditional Medicine Huaiqihuang (HQH) on the Protection of Nephropathy
Q95645882The Hippo Pathway as a Driver of Select Human Cancers

Search more.